Cargando…
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC doe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601266/ https://www.ncbi.nlm.nih.gov/pubmed/36290817 http://dx.doi.org/10.3390/curroncol29100540 |
_version_ | 1784817018136952832 |
---|---|
author | Poddar, Arpita Rao, Sushma R. Prithviraj, Prashanth Kannourakis, George Jayachandran, Aparna |
author_facet | Poddar, Arpita Rao, Sushma R. Prithviraj, Prashanth Kannourakis, George Jayachandran, Aparna |
author_sort | Poddar, Arpita |
collection | PubMed |
description | Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC does not respond to hormonal therapy, only partially responds to radio- and chemotherapy, and has limited targeted therapy options, thus underlining the critical need for better therapeutic treatments. Although immunotherapy based on immune checkpoint inhibition is emerging as a promising treatment option for TNBC patients, activation of cellular plasticity programs such as metabolic reprogramming (MR) and epithelial-to-mesenchymal transition (EMT) causes immunotherapy to fail. In this report, we review the role of MR and EMT in immune checkpoint dysregulation in TNBCs and specifically shed light on development of novel combination treatment modalities for this challenging disease. We highlight the clinical relevance of crosstalk between MR, EMT, and immune checkpoints in TNBCs. |
format | Online Article Text |
id | pubmed-9601266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96012662022-10-27 Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer Poddar, Arpita Rao, Sushma R. Prithviraj, Prashanth Kannourakis, George Jayachandran, Aparna Curr Oncol Review Breast cancer is one of the major causes of mortality in women worldwide. Accounting for 15–20% of all breast cancer diagnoses, the triple-negative breast cancer (TNBC) subtype presents with an aggressive clinical course, heightened metastatic potential and the poorest short-term prognosis. TNBC does not respond to hormonal therapy, only partially responds to radio- and chemotherapy, and has limited targeted therapy options, thus underlining the critical need for better therapeutic treatments. Although immunotherapy based on immune checkpoint inhibition is emerging as a promising treatment option for TNBC patients, activation of cellular plasticity programs such as metabolic reprogramming (MR) and epithelial-to-mesenchymal transition (EMT) causes immunotherapy to fail. In this report, we review the role of MR and EMT in immune checkpoint dysregulation in TNBCs and specifically shed light on development of novel combination treatment modalities for this challenging disease. We highlight the clinical relevance of crosstalk between MR, EMT, and immune checkpoints in TNBCs. MDPI 2022-09-23 /pmc/articles/PMC9601266/ /pubmed/36290817 http://dx.doi.org/10.3390/curroncol29100540 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Poddar, Arpita Rao, Sushma R. Prithviraj, Prashanth Kannourakis, George Jayachandran, Aparna Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title_full | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title_fullStr | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title_full_unstemmed | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title_short | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer |
title_sort | crosstalk between immune checkpoint modulators, metabolic reprogramming and cellular plasticity in triple-negative breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601266/ https://www.ncbi.nlm.nih.gov/pubmed/36290817 http://dx.doi.org/10.3390/curroncol29100540 |
work_keys_str_mv | AT poddararpita crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer AT raosushmar crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer AT prithvirajprashanth crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer AT kannourakisgeorge crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer AT jayachandranaparna crosstalkbetweenimmunecheckpointmodulatorsmetabolicreprogrammingandcellularplasticityintriplenegativebreastcancer |